Early and clear pathological diagnosis and pathological subtypes, accurate clinical staging and appropriate treatment plan are the prerequisites to obtain the best treatment effect. After diagnosis, patients should undergo standardized and reasonable treatment under the guidance of a specialist as soon as possible in order to obtain better results and minimize the chance of tumor recurrence. The treatment of lymphoma emphasizes a combination of chemotherapy-based therapy, radiotherapy in some specific clinical cases, and hematopoietic stem cell transplantation in patients with high-risk factors or relapsed lymphoma. With standardized treatment, more than half of the lymphoma patients can be cured, with Hodgkin’s lymphoma even reaching a cure rate of more than 80%. Currently, malignant lymphoma emphasizes stratified treatment based on the patient’s general condition, pathological staging and clinical risk factor assessment: for patients with high malignancy and expected poor outcome with conventional treatment, the intensity of treatment needs to be intensified or new treatments added with the aim of overcoming poor prognostic factors and achieving better outcomes; for patients who are expected to achieve better outcomes with conventional treatment, overtreatment needs to be avoided For patients who are expected to have a better outcome with conventional therapy, overtreatment needs to be avoided. Both chemotherapy and radiotherapy have certain adverse effects, so clinicians need to fully weigh the pros and cons before deciding on a treatment plan: only consider giving treatment if it can significantly benefit the patient (reduce pain, relieve symptoms, prolong survival or even cure). For example, for inert lymphoma of low malignancy, which is common in the elderly, regular review is possible when there is no indication for treatment, avoiding the toxicity of unnecessary treatment and ensuring the patient’s quality of life, and starting treatment only when there are some indications for treatment. Although autologous HSCT is widely used in relapsed refractory lymphoma, it is not used as the first-line treatment for Hodgkin’s lymphoma because the majority of Hodgkin’s lymphoma can be cured with conventional chemotherapy, and autologous HSCT does not improve the cure rate in these patients, but instead exposes patients to unnecessary treatment risks, associated toxicity, and increases the patient’s The cost of treatment is increased.